Drug intelligence / Profile preview

GT 389-255

Development stage: Discontinued
Lead developer: Peptimmune
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

GT 389-255 is a novel conjugate drug composed of a proprietary pancreatic lipase inhibitor and a fat-binding hydrogel polymer. It was developed for the treatment of obesity by inhibiting the absorption of dietary fat in the gastrointestinal tract. The mechanism involves inhibition of pancreatic lipase, thereby reducing fat absorption, combined with physical sequestration of dietary fats via the hydrogel component. The drug was initially developed by Genzyme and later involved Peptimmune as well[1][2][4][7][8]. Clinical development reached Phase 2 trials for obesity but was ultimately discontinued[2].

Targets

PNLIP (Pancreatic triacylglycerol lipase)

Beyond the preview

Go deeper on GT 389-255.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT 389-255.

Explore the full profile